Glaxosmithkline (LON:GSK) Rating Reaffirmed
Recently, In a recent report published on Wednesday, 2 December, Glaxosmithkline (LON:GSK) shares have had their Equal-weight Rating has restated by equity analysts at Morgan Stanley, who currently has a GBX 1450.00 Estimated Target Price on firm. This target by Morgan Stanley gives the possibile upside of 5.22% from the close price.
From a total of 24 analysts covering GlaxoSmithKline PLC (LON:GSK) stock, 6 rate it a ”Buy”, 4 a “Sell”, and 20 a ”Hold”. This means that 20% of the ratings are positive. The highest target price is GBX 1800 while the lowest target price is GBX 1218. The mean of all analyst targets is GBX 1468 with a 5.92% above today’s (GBX 1383.12) stock price. GlaxoSmithKline PLC was the topic of 91 analyst reports since July 28, 2015 according to the firm StockzIntelligence Inc. Bernstein maintained shares on December 1 with “Market Perform” rating. Berenberg maintained shares with “Hold” rating and GBX 1590 target share price in a report from a November 11. J.P. Morgan maintained GSK stock in a recent report from November 20 with “Neutral” rating. Oddo & Cie maintained the rating on November 6. Oddo & Cie has a “Reduce” rating and a GBX 1360 price target on shares. Finally, JP Morgan maintained the stock with “Neutral” rating in a report issued on a November 17.
The stock increased 2.38% or GBX 32.12 on December 2, striking GBX 1383.12. Approximately 7.13M shares of stock traded hands. GlaxoSmithKline plc (LON:GSK) has declined 9.96% since May 5, 2015 and is downtrending. It has underperformed by 9.76% the S&P500.
GlaxoSmithKline plc. is a healthcare firm that researches and develops pharmaceuticals, vaccines and consumer healthcare products. The company has a market cap of 67.34 billion GBP. The Firm operates in two divisions: Pharmaceuticals and Vaccines, and Consumer Healthcare. It has 6.8 P/E ratio. The Pharmaceuticals segment develops and makes medicines to treat a range of acute and chronic diseases.
According to Zacks Investment Research, “GlaxoSmithKline is one of the world’s leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.” Get a free copy of the Zacks research report on GlaxoSmithKline plc (GSK).